Skip to main content
Cardiosense Recieves FDA De Novo Classification for Novel Cardiac Technology Designed to Improve Care for Patients with Heart Failure Read the press release

Media Coverage

FDA Grants De Novo Status to Cardiosense PCWP Software for HFrEF

U.S. Food and Drug Administration logo

Keep reading